Alexander D Ramos1, Feliks Koyfman2, Kory Byrns3, Alan Wu4, Jay Yasen2, Lauren Elreda5, Srikanth Boddu1, Sammy Pishanidar2, Baxter Allen2, Rupa G Juthani1. 1. Department of Neurosurgery, Weill Cornell Medicine, New York, NY, USA. 2. Department of Neurology, Weill Cornell Medicine, New York, NY, USA. 3. Department of Radiology, New York-Presbyterian Queens Flushing, New York, NY, USA. 4. Division of Biostatistics and Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. 5. Division of Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA.
Abstract
BACKGROUND AND PURPOSE: COVID-19 is a known risk factor for stroke. There is limited data on the influence of demographics, risk factors, and hematologic function on outcomes in COVID-19 stroke patients. METHODS: All patients with acute ischemic or hemorrhagic stroke tested for COVID-19 and treated from March 13 through May 19, 2020 were retrospectively analyzed. COVID+ patients were compared to COVID- patients and a historical cohort from 2019. RESULTS: 84 patients with radiographic acute stroke from the 2020 study period and 152 patients in the historical cohort were included. Stroke incidence in COVID+ patients was 1.5%, with a significant decline in total stroke presentations during this period compared to 2019. 37 patients were COVID+ and 47 patients were COVID-. 32% of COVID+ stroke patients were Hispanic compared to 15% and 18% in the COVID- and 2019 cohorts respectively (p = 0.069 and 0.07). COVID+ stroke patients were younger, had higher rates of hemorrhagic conversion (p = 0.034), higher initial NIHSS (p < 0.001), increased cryptogenic stroke mechanism (p = 0.02), and higher mortality independent of COVID-19 severity. COVID+ patients had higher rates of thrombocytopenia (p = 0.02), and were less likely to be on antiplatelet therapy (p = 0.025). In multivariable analysis, only COVID-19 status independently predicted mortality. CONCLUSIONS: COVID status, independent of severity, was significantly associated with higher mortality in stroke patients. COVID+ stroke patients were younger and less likely to be on antiplatelets, with higher rates of thrombocytopenia, suggesting a possible role for antiplatelet use in this population.
BACKGROUND AND PURPOSE: COVID-19 is a known risk factor for stroke. There is limited data on the influence of demographics, risk factors, and hematologic function on outcomes in COVID-19 stroke patients. METHODS: All patients with acute ischemic or hemorrhagic stroke tested for COVID-19 and treated from March 13 through May 19, 2020 were retrospectively analyzed. COVID+ patients were compared to COVID- patients and a historical cohort from 2019. RESULTS: 84 patients with radiographic acute stroke from the 2020 study period and 152 patients in the historical cohort were included. Stroke incidence in COVID+ patients was 1.5%, with a significant decline in total stroke presentations during this period compared to 2019. 37 patients were COVID+ and 47 patients were COVID-. 32% of COVID+ stroke patients were Hispanic compared to 15% and 18% in the COVID- and 2019 cohorts respectively (p = 0.069 and 0.07). COVID+ stroke patients were younger, had higher rates of hemorrhagic conversion (p = 0.034), higher initial NIHSS (p < 0.001), increased cryptogenic stroke mechanism (p = 0.02), and higher mortality independent of COVID-19 severity. COVID+ patients had higher rates of thrombocytopenia (p = 0.02), and were less likely to be on antiplatelet therapy (p = 0.025). In multivariable analysis, only COVID-19 status independently predicted mortality. CONCLUSIONS: COVID status, independent of severity, was significantly associated with higher mortality in stroke patients. COVID+ stroke patients were younger and less likely to be on antiplatelets, with higher rates of thrombocytopenia, suggesting a possible role for antiplatelet use in this population.
Authors: Maximilian Ackermann; Stijn E Verleden; Mark Kuehnel; Axel Haverich; Tobias Welte; Florian Laenger; Arno Vanstapel; Christopher Werlein; Helge Stark; Alexandar Tzankov; William W Li; Vincent W Li; Steven J Mentzer; Danny Jonigk Journal: N Engl J Med Date: 2020-05-21 Impact factor: 91.245
Authors: Alexander E Merkler; Neal S Parikh; Saad Mir; Ajay Gupta; Hooman Kamel; Eaton Lin; Joshua Lantos; Edward J Schenck; Parag Goyal; Samuel S Bruce; Joshua Kahan; Kelsey N Lansdale; Natalie M LeMoss; Santosh B Murthy; Philip E Stieg; Matthew E Fink; Costantino Iadecola; Alan Z Segal; Marika Cusick; Thomas R Campion; Ivan Diaz; Cenai Zhang; Babak B Navi Journal: JAMA Neurol Date: 2020-07-02 Impact factor: 18.302
Authors: Sabrina M Heman-Ackah; YouRong Sophie Su; Michael Spadola; Dmitriy Petrov; H Isaac Chen; James Schuster; Timothy Lucas Journal: Neurosurgery Date: 2020-08-01 Impact factor: 4.654
Authors: Shadi Yaghi; Koto Ishida; Jose Torres; Brian Mac Grory; Eytan Raz; Kelley Humbert; Nils Henninger; Tushar Trivedi; Kaitlyn Lillemoe; Shazia Alam; Matthew Sanger; Sun Kim; Erica Scher; Seena Dehkharghani; Michael Wachs; Omar Tanweer; Frank Volpicelli; Brian Bosworth; Aaron Lord; Jennifer Frontera Journal: Stroke Date: 2020-05-20 Impact factor: 7.914
Authors: Alireza Radmanesh; Anna Derman; Yvonne W Lui; Eytan Raz; John P Loh; Mari Hagiwara; Maria J Borja; Elcin Zan; Girish M Fatterpekar Journal: Radiology Date: 2020-05-21 Impact factor: 11.105
Authors: Raymond Pranata; Ian Huang; Michael Anthonius Lim; Eka Julianta Wahjoepramono; Julius July Journal: J Stroke Cerebrovasc Dis Date: 2020-05-14 Impact factor: 2.136
Authors: Michał Sojka; Anna Drelich-Zbroja; Maryla Kuczyńska; Mateusz Cheda; Izabela Dąbrowska; Ewa Kopyto; Izabela Halczuk; Monika Zbroja; Weronika Cyranka; Tomasz Jargiełło Journal: Int J Environ Res Public Health Date: 2022-09-19 Impact factor: 4.614